Nanopharma Cerulean Advances Cancer Particle, Looks Ahead To siRNA

Nanotech platform company Cerulean Pharma Inc. has a high-quality problem. The Cambridge, Mass., start-up is poised to take its lead candidate into Phase IIb cancer trials, but the young company must choose among several cancer types in which the nanoparticle shows go-ahead activity

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet